LEVERKUSEN, Germany, Nov. 14, 2024 /PRNewswire/ — WuXi Biologics (“WuXi Bio”) (2269.HK), a prominent international Agreement Analysis, Building, and Production Group (CRDMO), introduced that it is going to support its drug product (DP) functions on the corporate’s facility in Leverkusen, Germany, with a untouched sterile filling order for prefilled syringes (PFS) the usage of isolator era.
Development of the untouched order will optimize the design of the Leverkusen facility’s production form to be extra environment friendly for multi-product CRDMO utility. The untouched order, with its capacity to take care of a couple of syringe sizes (1 ml, 2.25 ml, and three ml) at a filling price of as much as 400 syringes in step with little, allows versatile GMP manufacturing of no less than 17 million syringes each time. This might be along with the prevailing sterile filling and freeze-drying order that has an annual capability of roughly ten million doses. Development is scheduled to begin not too long ago, with the purpose of attaining GMP compliance via 2026.
Dr. Chris Chen, CEO of WuXi Biologics, commented, “The increased capacity in Germany will allow us to continue to meet growing client demand for DP services, especially for prefilled syringes. Such investments further demonstrate our commitment to the Global Dual Sourcing strategy that ensures materials can be sourced and products manufactured at multiple sites within the company’s global network. As a trusted partner to global healthcare companies and a significant contributor to the local community, we are dedicated to providing efficient and cost-effective processes that enable our clients to bring breakthrough therapies to patients.”
About WuXi Biologics
WuXi Biologics (reserve code: 2269.HK) is a prominent international Agreement Analysis, Building and Production Group (CRDMO) providing end-to-end answers that allow companions to find, manufacture and form biologics – from thought to commercialization – for the advantage of sufferers international.
With over 12,000 professional workers in China, america, Eire, Germany and Singapore, WuXi Biologics leverages its applied sciences and experience to lend consumers with environment friendly and cost-effective biologics discovery, building and production answers. As of June 30, 2024, WuXi Biologics is supporting 742 built-in shopper initiatives, together with 16 in industrial production (except for COVID CMO and non-COVID dormant CMO initiatives).
WuXi Biologics perspectives Environmental, Social, and Governance (ESG) tasks as an integral trait of our ethos and industry technique, and we try to grow to be an ESG chief within the biologics CRDMO sector. Our amenities utility next-generation biomanufacturing applied sciences and clean-energy assets. Now we have additionally established an ESG committee led via our CEO to persuade the great ESG technique and its implementation, improving our loyalty to sustainability.
For more info about WuXi Biologics, please discuss with: www.wuxibiologics.com.
Contacts
Media
[email protected]
Trade
[email protected]
WANT YOUR COMPANY’S NEWS FEATURED ON PRNEWSWIRE.COM?
440k+
Newsrooms &
Influencers
9k+
Virtual Media
Retailers
270k+
Newshounds
Opted In
